PURPOSE: This study aims to evaluate a cytochrome P450-based tamoxifen-isoflavone interaction and to determine the mechanisms responsible for inhibitory effects of isoflavones (e.g., genistein) on the formation of alpha-hydroxytamoxifen. METHODS: Metabolism studies were performed in vitro using female rat liver microsomes. The effects of genistein and an isoflavone mixture on tamoxifen metabolism and the inhibition mechanism were determined using standard kinetic analysis, preincubation, and selective chemical inhibitors of P450. RESULTS: Metabolism of tamoxifen was saturable with Km values of 4.9+/-0.6, 14.6+/-2.2, 25+/-5.9 microM and Vmax values of 34.7+/-1.4, 297.5+/-19.2, 1867+/-231 pmol min(-1) mg(-1) for a-hydroxylation, N-desmethylation, and N-oxidation, respectively. Genistein (25 microM) inhibited alpha-hydroxylation at 2.5 microM tamoxifen by 64% (p < 0.001) but did not affect the 4-hydroxylation, N-desmethylation, and N-oxidation. A combination of three (genistein, daidzein, and glycitein) to five isoflavones (plus biochanin A and formononetin) inhibited tamoxifen alpha-hydroxylation to a greater extent but did not decrease the formation of identified metabolites. The inhibition on alpha-hydroxylation by genistein was mixed-typed with a Ki, value of 10.6 microM. Studies using selective chemical inhibitors showed that tamoxifen alpha-hydroxylation was mainly mediated by rat CYP1A2 and CYP3A1/2 and that genistein 3'-hydroxylation was mainly mediated by rat CYP1A2, CYP2C6 and CYP2D1. CONCLUSIONS: Genistein and its isoflavone analogs have the potential to decrease side effects of tamoxifen through metabolic interactions that inhibit the formation of a-hydroxytamoxifen via inhibition of CYP1A2.
PURPOSE: This study aims to evaluate a cytochrome P450-based tamoxifen-isoflavone interaction and to determine the mechanisms responsible for inhibitory effects of isoflavones (e.g., genistein) on the formation of alpha-hydroxytamoxifen. METHODS: Metabolism studies were performed in vitro using female rat liver microsomes. The effects of genistein and an isoflavone mixture on tamoxifen metabolism and the inhibition mechanism were determined using standard kinetic analysis, preincubation, and selective chemical inhibitors of P450. RESULTS: Metabolism of tamoxifen was saturable with Km values of 4.9+/-0.6, 14.6+/-2.2, 25+/-5.9 microM and Vmax values of 34.7+/-1.4, 297.5+/-19.2, 1867+/-231 pmol min(-1) mg(-1) for a-hydroxylation, N-desmethylation, and N-oxidation, respectively. Genistein (25 microM) inhibited alpha-hydroxylation at 2.5 microM tamoxifen by 64% (p < 0.001) but did not affect the 4-hydroxylation, N-desmethylation, and N-oxidation. A combination of three (genistein, daidzein, and glycitein) to five isoflavones (plus biochanin A and formononetin) inhibited tamoxifen alpha-hydroxylation to a greater extent but did not decrease the formation of identified metabolites. The inhibition on alpha-hydroxylation by genistein was mixed-typed with a Ki, value of 10.6 microM. Studies using selective chemical inhibitors showed that tamoxifen alpha-hydroxylation was mainly mediated by ratCYP1A2 and CYP3A1/2 and that genistein 3'-hydroxylation was mainly mediated by ratCYP1A2, CYP2C6 and CYP2D1. CONCLUSIONS:Genistein and its isoflavone analogs have the potential to decrease side effects of tamoxifen through metabolic interactions that inhibit the formation of a-hydroxytamoxifen via inhibition of CYP1A2.
Authors: Ming Hu; Kristopher Krausz; Jun Chen; Xia Ge; Jianqi Li; Harry L Gelboin; Frank J Gonzalez Journal: Drug Metab Dispos Date: 2003-07 Impact factor: 3.922
Authors: Marjorie G Busby; A Robert Jeffcoat; LeAnne T Bloedon; Matthew A Koch; Tracy Black; Kelly J Dix; William D Heizer; Brian F Thomas; Judith M Hill; James A Crowell; Steven H Zeisel Journal: Am J Clin Nutr Date: 2002-01 Impact factor: 7.045
Authors: R C Bergan; E Reed; C E Myers; D Headlee; O Brawley; H K Cho; W D Figg; A Tompkins; W M Linehan; D Kohler; S M Steinberg; M V Blagosklonny Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: Guangyi Yang; Song Gao; Rongjin Sun; Taijun Yin; Ming Hu Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2015-08-07 Impact factor: 3.205
Authors: Neela Guha; Marilyn L Kwan; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Bette J Caan Journal: Breast Cancer Res Treat Date: 2009-02-17 Impact factor: 4.872
Authors: Young H Ju; Daniel R Doerge; Kellie A Woodling; James A Hartman; Jieun Kwak; William G Helferich Journal: Carcinogenesis Date: 2008-07-16 Impact factor: 4.944
Authors: Zhen Yang; Song Gao; Taijun Yin; Kaustubh H Kulkarni; Yang Teng; Ming You; Ming Hu Journal: J Pharm Biomed Anal Date: 2009-11-26 Impact factor: 3.935